Biocon Past Earnings Performance

Past criteria checks 4/6

Biocon's earnings have been declining at an average annual rate of -7.7%, while the Biotechs industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 19.3% per year. Biocon's return on equity is 6.1%, and it has net margins of 8.2%.

Key information

-7.7%

Earnings growth rate

-8.0%

EPS growth rate

Biotechs Industry Growth	5.1%
Revenue growth rate	19.3%
Return on equity	6.1%
Net Margin	8.2%
Next Earnings Update	16 May 2024

Recent past performance updates

Recent updates

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Mar 20

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Feb 12

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Jan 23

Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Dec 17

Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?

Sep 05

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 13

Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate

May 26

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Mar 28

Biocon (NSE:BIOCON) Seems To Use Debt Quite Sensibly

Dec 27

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Nov 25

Revenue & Expenses Breakdown
Beta

How Biocon makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:BIOCON Revenue, expenses and earnings (INR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	146,125	12,002	26,439	-119
30 Sep 23	135,999	4,984	24,819	-1,238
30 Jun 23	124,573	4,197	23,998	-2,156
31 Mar 23	111,742	4,627	23,331	-3,922
31 Dec 22	98,091	3,881	22,558	-5,606
30 Sep 22	90,422	6,170	21,920	-5,825
30 Jun 22	85,629	7,084	21,305	-5,768
31 Mar 22	81,840	6,484	20,539	-4,764
31 Dec 21	75,800	6,727	20,252	-4,050
30 Sep 21	72,632	6,542	19,935	-3,581
30 Jun 21	71,726	6,852	19,466	-3,530
31 Mar 21	71,431	7,405	17,485	-3,507
31 Dec 20	68,913	5,996	16,778	-3,607
30 Sep 20	67,571	6,362	15,906	-3,596
30 Jun 20	65,796	6,870	15,120	-3,568
31 Mar 20	63,005	7,771	16,545	-3,458
31 Dec 19	63,150	8,385	13,910	-3,001
30 Sep 19	61,077	8,529	13,093	-2,746
30 Jun 19	58,565	9,919	12,449	-2,757
31 Mar 19	55,144	9,053	11,653	-2,699
31 Dec 18	51,551	8,220	11,087	-2,421
30 Sep 18	46,722	6,967	10,496	-2,449
30 Jun 18	43,198	4,108	9,862	-1,993
31 Mar 18	41,234	3,724	9,311	-1,747
31 Dec 17	38,792	3,695	8,708	-1,522
30 Sep 17	38,589	4,489	8,297	-1,257
30 Jun 17	38,361	5,268	7,846	-1,324
31 Mar 17	38,911	6,121	7,510	-1,283
31 Dec 16	40,487	11,633	7,458	-1,472
30 Sep 16	38,110	10,961	7,038	-1,468
30 Jun 16	36,539	9,388	6,665	-1,378
31 Mar 16	33,474	5,504	6,128	-1,320
31 Dec 15	32,997	7,367	8,595	-202
30 Sep 15	32,325	7,247	8,366	-196
30 Jun 15	31,528	5,207	8,223	-272
31 Mar 15	30,898	4,974	5,371	-1,321
31 Dec 14	29,807	4,091	7,565	-386
30 Sep 14	29,168	4,231	7,360	-561
30 Jun 14	29,014	4,232	7,137	-585
31 Mar 14	28,773	4,138	7,035	-642
31 Dec 13	28,180	5,493	6,636	47
30 Sep 13	27,510	5,361	6,428	47
30 Jun 13	26,083	5,229	6,232	47

Quality Earnings: BIOCON has high quality earnings.

Growing Profit Margin: BIOCON's current net profit margins (8.2%) are higher than last year (4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BIOCON's earnings have declined by 7.7% per year over the past 5 years.

Accelerating Growth: BIOCON's earnings growth over the past year (209.3%) exceeds its 5-year average (-7.7% per year).

Earnings vs Industry: BIOCON earnings growth over the past year (209.3%) exceeded the Biotechs industry -2.9%.

Biocon Past Earnings Performance

Past criteria checks 4/6

Key information

Recent past performance updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings released: ₹0.35 loss per share (vs ₹1.57 profit in 3Q 2022)

Biocon Limited to Report Q2, 2024 Results on Nov 06, 2023

Recent updates

Insider recently sold ₹5.3m worth of stock

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Investor sentiment improves as stock rises 17%

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Insider recently sold ₹1.8m worth of stock

Biocon Limited Announces the Resignation of Prasad Deshpande as Head SCM and Central Engineering, Senior Management Personnel, Effective January 16, 2024

Biocon Limited Appoints Nicholas Robert Haggar as an Independent Director

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Biocon Limited Announces Management Changes

Insider recently sold ₹13m worth of stock

Group Chief Information Officer recently sold ₹3.2m worth of stock

Biocon Limited Appoints Peter Bains as Biocon Group Chief Executive Officer

Insider recently sold ₹1.6m worth of stock

Consensus EPS estimates fall by 16%

Biocon Limited Approves Appointment of Ms. Rekha Mehrotra Menon as an Independent Director

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Biocon Limited Announces Cessation of Vijay Kumar Kuchroo as a Director

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Insider selling

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Upcoming dividend of ₹1.50 per share at 0.6% yield

Insider recently sold ₹5.3m worth of stock

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

Biocon Limited, Annual General Meeting, Aug 11, 2023

Biocon Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 8, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Insider recently sold ₹2.3m worth of stock

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Insider recently sold ₹1.1m worth of stock

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 17%

Price target decreased by 7.4% to ₹316

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Third quarter 2023 earnings released: ₹0.35 loss per share (vs ₹1.57 profit in 3Q 2022)

Biocon Limited to Report Q2, 2024 Results on Nov 06, 2023

Consensus forecasts updated

Biocon Limited to Report Q3, 2023 Results on Feb 14, 2023

Insider recently sold ₹13m worth of stock

Insider recently sold ₹40m worth of stock

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Insider recently sold ₹4.2m worth of stock

Consensus forecasts updated

Biocon Limited Announces Board Changes

Second quarter 2023 earnings released: EPS: ₹0.39 (vs ₹1.16 in 2Q 2022)

Biocon Limited to Report Q2, 2023 Results on Nov 14, 2022

Insider recently sold ₹4.1m worth of stock

Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?

Insider recently sold ₹3.8m worth of stock

Price target decreased to ₹379

Consensus EPS estimates fall by 16%

Biocon Limited Announces Directors Resignation

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocon Limited to Report Q3, 2023 Results on Jan 24, 2023

Biocon Limited to Report Q1, 2023 Results on Jul 27, 2022

Biocon Limited (NSEI:BIOCON) agreed to acquire 26% stake in AMPYR Renewable Energy Resources Eleven Private Limited for INR 75 million.

Upcoming dividend of ₹0.50 per share

Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate

Revenue & Expenses Breakdown
Beta